Renaissance Capital logo

Pyxis Oncology Priced, Nasdaq: PYXS

Preclinical biotech developing antibody therapies for solid and hematologic tumors.

Industry: Health Care

Latest Trade: $2.08 -1.74 (-45.5%)

First Day Return: -17.5%

Return from IPO: -76.1%

Industry: Health Care

We are a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. We develop our product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since our launch in 2019, we have developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that we are developing as monotherapies and in combination with other therapies. We take a holistic view of attacking the key drivers of tumor growth and progression within the tumor microenvironment, or TME, including targeting of tumor antigens and modulating the innate and adaptive immune response. The TME is an immunosuppressive environment consisting of cancer cells and stroma, which includes the blood vessels, immune cells, fibroblasts, signaling molecules, and the extracellular matrix that surrounds the tumor. The TME plays multiple roles in tumor formation, progression and metastasis as well as anti-tumor immune activity. We are developing our ADC product candidates and mAb preclinical discovery programs to precisely target key modulators of the adaptive and innate immune system within the TME for difficult-to-treat solid and hematologic tumors.
more less
IPO Data
IPO File Date 09/17/2021
Offer Price $16.00
Price Range $14.00 - $16.00
Offer Shares (mm) 10.5
Deal Size ($mm) $168
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 10/07/2021
Offer Price $16.00
Price Range $14.00 - $16.00
Offer Shares (mm) 10.5
Deal Size ($mm) $168
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
BofA Securities
Jefferies
more
Company Data
Headquarters Cambridge, MA, United States
Founded 2018
Employees at IPO 38
Website www.pyxisoncology.com

Pyxis Oncology (PYXS) Performance